Sinoviortesis con radioisótopos en hemofilia: Experiencia de un centro en Chile
- Autores: Verónica Soto, María Mercedes Morales, Patricio Morales, Andrés Oyarzún, Daniela Cortez, Macarena González
- Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 147, Nº. 5, 2019, págs. 568-573
- Idioma: español
- Títulos paralelos:
- Radionuclide synoviorthesis in hemophilia: experience in 107 patients
- Enlaces
-
Resumen
Background: In patients with hemophilia, radionuclide synoviorthesis, or the intra-articular injection of a radionuclide to decrease the synovial hypertrophy tissue, aims to decrease or avoid hemarthrosis. Aim: To evaluate the effectiveness of radionuclide synoviorthesis in hemophilia. Material and Methods: Observational retrospective study of the evolution of 107 male patients aged 3 to 54 years who were subjected to radionuclide synoviorthesis between 2007 and 2015. Results: Of 164 treated joints, in 65% treatment was successful, (defined as zero to two hemarthroses and absence of synovitis during the follow up period), in 17% it was partially successful (defined as two or less hemarthroses, but persistence of the synovitis) and failed in 18% of the procedures. No important complications were recorded. Conclusions: Radionuclide synoviorthesis has an overall 82% success rate, is minimally invasive, can be used at any age and is inexpensive We recommend its implementation in Chilean hemophilia treatment centers.
